Deanna Derusso
Internal Medicine · Leesburg, VANPI 1962463448
Payments from drug & device makers
Across 200 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$415
- AstraZeneca$317
- Lilly USA, LLC$254
- Bausch Health US, LLC$222
- Pfizer$144
- plus $699 from 17 others
What the payments were for
- Food & beverage$3,671100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 91 | $1,620 |
| AbbVie(2 entities) | 22 | $415 |
| AstraZeneca(2 entities) | 19 | $317 |
| Lilly USA, LLC | 15 | $254 |
| Bausch Health US, LLC | 11 | $222 |
| Pfizer | 6 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $119 |
| Axsome Therapeutics, Inc. | 5 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $98 |
| GSK | 3 | $47 |
| Endo Pharmaceuticals Inc. | 2 | $45 |
| Antares Pharma, Inc. | 2 | $39 |
| Nestle Healthcare Nutrition Inc. | 2 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $28 |
| Mayne Pharma Commercial LLC | 1 | $26 |
| Bardy Diagnostics, Inc. | 1 | $25 |
| Exact Sciences | 1 | $25 |
| IBSA Pharma Inc. | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Merck | 1 | $20 |
| Medtronic | 1 | $19 |
| Avion Pharmaceuticals | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
How this compares
$3,671 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 22 | $29,745 |
| SynthroidLevothyroxine Sodium | 14 | $1,938 |
| Methylprednisolone | 25 | $429 |
| Potassium Chloride | 20 | $423 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 19 | $351 |
| Terazosin Hcl | 17 | $326 |
| ValacyclovirValacyclovir Hcl | 11 | $323 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $274 |
| Levothyroxine Sodium | 17 | $258 |
| Metoprolol Succinate | 17 | $227 |
| Olmesartan Medoxomil | 12 | $218 |
| Oxycodone Hcl | 13 | $140 |
| Sertraline Hcl | 15 | $130 |
| Atorvastatin Calcium | 19 | $115 |
| Amlodipine Besylate | 34 | $109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,620 | $29,74522 claims |
| AbbVieSynthroid | $415 | $1,93814 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $28 | $25817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Leesburg
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.